Stay updated on Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed, indicating a minor update to the site. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedGlossary display added. The study description now includes Telisotuzumab Vedotin dosing, 1:1 randomization with docetaxel, enrollment of about 698 participants across ~330 sites, and expanded lists of investigators and locations.SummaryDifference0.8%

- Check39 days agoChange DetectedRevision: v3.3.4 updated on the Study Details page, replacing v3.3.3. The update appears to be a minor revision with no changes to study details, eligibility criteria, or outcomes.SummaryDifference0.0%

- Check67 days agoChange DetectedExpanded the Study Details by adding a comprehensive list of enrollment sites across the United States and multiple countries and removed the HHS Vulnerability Disclosure section.SummaryDifference4%

- Check89 days agoChange DetectedRevision label in the page footer updated to v3.3.2; Revision v3.3.1 was removed.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.